Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10164693
• 负责人: JOHN MORRIS
• 金额: $ 306.61万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10164693
• 关键词: 3-Dimensional; Address; Age; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Area; Autopsy; Basic Science; Behavioral; Biological Markers; Biopsy; Blood; Brain; Cerebrospinal Fluid; Clinical; Clinical Sciences; Cognitive; Collaborations; Communities; Consent; DNA; Data; Data Set; Dementia; Dermal; Development; Diagnosis; Disease; Ensure; Environment; Etiology; Faculty; Fibroblasts; Financial Support; Fostering; Functional Magnetic Resonance Imaging; Funding; Genetic; Genetic Markers; Goals; Grant; Image; International; Knowledge; Magnetic Resonance Imaging; Memory; Molecular Profiling; Multicenter Studies; National Institute on Aging; Nuclear Pore Complex; Participant; Pathogenesis; Pathologic; Performance; Persons; Plasma; Population; Positron-Emission Tomography; Prevention trial; Productivity; Psychometrics; Research; Research Personnel; Research Project Grants; Resources; Rest; Scientist; Services; Skin; Students; Symptoms; Thinking; Tissues; Training; Universities; Washington; Work; base; brain tissue; career development; clinical center; clinical phenotype; cohort; data management; design; disorder prevention; education research; effective therapy; faculty support; induced pluripotent stem cell; innovation; instrument; metropolitan; mild cognitive impairment; molecular marker; multidisciplinary; multimodality; neuropathology; normal aging; outreach; pre-clinical; prevent; programs; racial diversity; recruit; repository; skills; statistics; student training; tau Proteins

Overall Project Summary The Washington University Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) initiates, fosters, and supports the performance of innovative, cutting-edge research on Alzheimer disease (AD) and related dementias (ADRD) with regard to the etiology, pathogenesis, diagnosis, treatment, and prevention of disease. The Knight ADRC's efforts thus fully align with the primary goal of the National Alzheimer's Project Act of 2011, “to prevent and effectively treat ADRD by 2025”. We provide well- characterized research participants (persons with symptomatic AD and age-matched controls), their clinical, psychometric, and imaging data, and their tissue (DNA, CSF, plasma, dermal fibroblasts, iPSCs, brain tissue) to research projects. We also provide intellectual and financial support to scientists at Washington University, at other Alzheimer Disease Centers, and the research community nationally and internationally and engage in formal and informal collaborations, including multi-disciplinary/multi-Center studies and the initiatives sponsored by the National Institute on Aging, the National Alzheimer Coordinating Center, and the National Centralize Repository for ADRD. Historically, our Center has focused on the earliest stages of dementia to identify the initial clinical and pathologic changes that distinguish AD from normal aging. Our approach is balanced between clinical and basic science domains with emphasis on interdisciplinary efforts. We will continue our training of students, fellows and junior faculty in clinical and basic science research skills. We will continue to engage in outreach activities to transfer information on ADRD to lay and professional audiences. We are committed to assuring that our research cohort reflects the racial diversity of the greater metropolitan St. Louis area and will continue activities that promote the inclusion of these populations in research. This renewal application includes seven Cores, plus the new Research Education Component (REC): A: Administration, B: Clinical, C: Data Management and Statistics, D: Neuropathology, E: Outreach, Recruitment, and Engagement, F: Biomarker, G: Genetics and High Throughput -Omics.

总体项目摘要 华盛顿大学的查尔斯·F. Joanne Knight阿尔茨海默病研究中心（Knight ADRC）发起、促进和支持阿尔茨海默病创新、前沿研究的绩效 疾病（AD）和相关痴呆（ADRD）的病因、发病机制、诊断、治疗， 和预防疾病。因此，Knight ADRC的努力完全符合国家的主要目标。 2011年阿尔茨海默病项目法案，“到2025年预防和有效治疗ADRD”。我们提供良好的- 特征研究参与者（有症状的AD患者和年龄匹配的对照组），他们的临床， 心理测量和成像数据及其组织（DNA、CSF、血浆、真皮成纤维细胞、iPSC、脑组织） to research研究projects项目.我们还为华盛顿大学的科学家提供智力和财政支持， 在其他阿尔茨海默病中心，以及国内和国际的研究界， 正式和非正式合作，包括多学科/多中心研究和倡议 由国家老龄化研究所，国家阿尔茨海默病协调中心和国家 为ADRD集中存储库。从历史上看，我们的中心一直专注于痴呆症的早期阶段， 识别AD与正常衰老的区别的初始临床和病理变化。我们的做法是 临床和基础科学领域之间的平衡，强调跨学科的努力。我们将 继续对学生、研究员和初级教师进行临床和基础科学研究技能的培训。我们将 继续开展外联活动，向非专业和专业受众传递关于ADRD的信息。 我们致力于确保我们的研究群体反映了大都市的种族多样性 圣路易斯地区，并将继续开展活动，促进这些人口纳入研究。 此更新申请包括七个核心，加上新的研究教育组件（REC）： A：管理，B：临床，C：数据管理和统计，D：神经病理学，E：外展， 招募和参与，F：生物标志物，G：遗传学和高产量-组学。